Exploratory Study of TRBC1/2-Targeted CAR-T Cell Therapy in Relapsed/Refractory Peripheral T-Cell Lymphoma
NCT ID: NCT07164560
Last Updated: 2025-09-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
45 participants
INTERVENTIONAL
2025-09-01
2028-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies
NCT04828174
Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
NCT02541370
Clinical Study of Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 for Relapsed/Refractory B-ALL and NHL
NCT06879262
A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL
NCT04860817
Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma
NCT03258047
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will be conducted in two parts:
Phase I (Dose Escalation):
A dose-escalation study will be carried out following the conventional "3+3" design, with one dose level administered via intravenous infusion. Each cohort will enroll 3 to 6 patients. After the initial infusion, patients will be observed for at least 28 days for safety evaluation, followed by long-term follow-up of up to 2 years post-infusion.
Phase II (Dose Expansion):
Based on safety, in vivo expansion and persistence of TRBC1/2 CAR-T cells, and preliminary efficacy results from Phase I, the recommended dose and administration schedule will be determined. Approximately 30 eligible patients will then be enrolled to further assess safety and efficacy at the selected dose. Following the first infusion of TRBC1/2 CAR-T cells, patients will continue in long-term follow-up for up to 2 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PB TRBC1/2 CAR-T
Anti-TRBC1 CAR-T cells
lentiviral vector-transducted peripheral blood-derived T cells to express anti-TRBC1 CAR
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anti-TRBC1 CAR-T cells
lentiviral vector-transducted peripheral blood-derived T cells to express anti-TRBC1 CAR
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Voluntarily agree to participate in this study and provide signed informed consent.
2. Age 18 to 75 years, male or female.
3. Diagnosis of relapsed/refractory PTCL, defined as failure of ≥1 prior line of therapy. Eligible histologic subtypes include (but are not limited to):
Angioimmunoblastic T-cell lymphoma (AITL) Anaplastic large cell lymphoma (ALCL) Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS)
4. Estimated life expectancy ≥12 weeks.
5. TRBC1/2-positive tumor tissue (≥20% by immunohistochemistry) OR TCR gene rearrangement confirmed by PCR or NGS.
6. ECOG performance status of 0-2.
7. Adequate organ function as defined below:
ALT and AST ≤ 2.5 × upper limit of normal (ULN) Creatinine clearance (Cockcroft-Gault) ≥ 60 mL/min Total bilirubin ≤ 1.5 × ULN Left ventricular ejection fraction (LVEF) ≥ 50% Baseline oxygen saturation \> 92% on room air
Hematology:
Phase Ia: ANC \> 1500/mm³, platelets \> 75 × 10⁹/L, hemoglobin \> 9 g/dL Phase Ib: ANC \> 1000/mm³, platelets \> 50 × 10⁹/L, hemoglobin \> 8 g/dL
8. ≥3 months since prior autologous hematopoietic stem cell transplantation.
9. Prior CAR-T therapy targeting a different antigen is permitted if lack of efficacy was confirmed after ≥3 months of evaluation, or if complete remission (CR) was achieved but relapse occurred.
10. Women of childbearing potential must have a negative pregnancy test prior to enrollment. All patients (male and female) must agree to use effective contraception during the study.
11. Presence of at least one measurable lesion.
12. All approved prior anti-tumor therapies (including systemic chemotherapy, total body irradiation, or immunotherapy) must have been completed ≥3 weeks before study drug administration; for non-chemotherapy targeted agents, a washout period of ≥2 weeks is required.
Exclusion Criteria
1. History of allergy to any component of the cell product.
2. History of another malignancy that has not achieved remission.
3. Prior allogeneic hematopoietic stem cell transplantation or solid organ transplantation.
4. Receipt of gene therapy within the past 3 months.
5. Uncontrolled systemic active infection (with the exception of simple urinary tract infection or bacterial pharyngitis). Prophylactic use of antibiotics, antivirals, or antifungal agents is permitted.
6. Active hepatitis B infection (HBsAg positive; however, patients with HBV-DNA \<10³ copies/mL are not excluded), active hepatitis C virus infection (including carriers), syphilis, or other acquired or congenital immunodeficiency diseases, including but not limited to HIV infection.
7. New York Heart Association (NYHA) Class III or IV heart failure.
8. Unresolved toxicity from prior anti-tumor therapy (defined as CTCAE v5.0 Grade \>1, with the exception of fatigue, anorexia, and alopecia).
9. Evidence of central nervous system (CNS) involvement at screening, or clinically significant CNS disease such as a history of seizures or other CNS disorders.
10. Prior exposure to any agent specifically targeting TRBC1/2.
11. Lactating women who are unwilling to discontinue breastfeeding.
12. Any other condition that, in the opinion of the investigator, may increase patient risk or interfere with the study results.
13. Autoimmune disease requiring immunosuppressive therapy.
14. Use of immunosuppressive agents or therapeutic doses of corticosteroids (defined as prednisone \>20 mg/day or equivalent) within 7 days prior to leukapheresis, or use of hematopoietic growth factors such as G-CSF. Physiological replacement therapy, topical, or inhaled corticosteroids are permitted.
15. Receipt of chemotherapy, targeted therapy, immunotherapy, or radiotherapy within 3 days prior to leukapheresis.
16. Participation in another clinical trial within 4 weeks or within 5 half-lives of the investigational product (whichever is shorter) prior to leukapheresis.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University Cancer Hospital & Institute
OTHER
Ruijin Hospital
OTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
2nd Affiliated Hospital,School of Medicine,Zhejiang University
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-0638
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.